



Breast Symposium

Wednesday, February 27th 2013

Crowne Plaza Hotel Santry, Dublin

10.00 – 11.00 Registration

11.00-12.00 Light lunch

Session 1 HER2+ Breast Cancers

Introduction and welcome: Dr Jacintha O'Sullivan, Hon. Secretary, IACR

Chair: Dr Lorraine O'Driscoll, Trinity College Dublin

12.00-12.15 *Prof John Crown*, Director MTCI, St Vincent's University

Hospital/Dublin City University:

"Molecular Therapeutics For Cancer Ireland: A New Vision For

Translational Cancer Research"

12.15-12.45 **Prof John Crown**, Director MTCI, St Vincent's University

Hospital/Dublin City University:

"Targeting the Her2 Pathway in Breast Cancer"

12.45-13.15 *Prof Dennis Slamon*, Director, Clinical/Translational Research,

Jonsson Comprehensive Cancer Center, University of California Los

Angeles: "Personalized Therapies for Breast Cancer"

13.15-13.30 Proffered Paper 1 - **S. Rani** Trinity College Dublin

"Exosome-Mediated Response to Her-Targeted Therapies in

Breast Cancer"

Session 2: Pathways to Progression

Chair: Dr Patrick Kiely, University of Limerick

13.30-14.00 **Prof Bryan Hennessy,** Royal College of Surgeons in Ireland: "The

PI3K Pathway in Breast Cancer"





Breast Symposium Wednesday, February 27th 2013

14.00-14.30	Prof Igor Roninson, University of South Carolina: "CDK8: a new pleiotropic target for breast cancer therapy"	
14.30-14.45	Proffered Paper 2 – K. Orr, Queens University Belfast "The Identification of TBXA2R as a Driver Of Proliferation in Triple Negative Breast Cancer"	
14.45-15.00	Proffered Paper 3 – <i>J. Bolger,</i> Royal College of Surgeons in Ireland "Global Analysis Of The SRC-1 And HOXC11 Transcriptomes Identifies a Novel Role for SRC-1 and HOXC11 in Suppressing Luminal A Markers in Breast Cancer."	
15.00-15.30	Coffee Break	
15.00-17.00	Session 3: Therapeutic Resistance	
Chair: Dr Ann Hopkins, Royal College of Surgeons in Ireland		
15.30-16.00	Prof Leonie Young, Royal College of Surgeons in Ireland: "SRC-1 mediation of cancer cell reprogramming in endocrine resistant breast cancer"	
16.00-16.30	Dr Paul Mullan, Queens University Belfast: 'Unravelling transcription control mechanisms in breast cancer – opportunities for novel treatments?'	
16.30-16.45	Proffered Paper 4 – P. O'Leary University College Dublin "The Antioxidant Enzyme, Peroxiredoxin-1, Protects The Estrogen Receptor Against Oxidative Stress-Induced Suppression and Is Correlated With Differential Outcome Of Patients With Breast Cancer"	





Breast Symposium Wednesday, February 27th 2013

16.45-17.00 Proffered Paper 5 – *E. Hughes*, Royal College of Surgeons in Ireland

"Endocrine Therapy Can Induce Disease Progression and

Metastasis in Breast Cancer"

17.00-18.00 Session 4: MTCI Lecture

Chair: Dr Darran O'Connor, University College Dublin

17.00-18.00 **Prof William Gallagher** University College Dublin:

"Molecular Determinants of Breast Tumour Progression and

Therapeutic Response: Tackling the Validation Bottleneck"

18.00 Awarding of the 'Beatson Medal' and Prize for best

Proffered paper – Kindly sponsored by Breast Cancer

Ireland





Main IACR Meeting

Crowne Plaza Hotel, Santry Thursday 28th February 2013

08.45-09.00 Welcome Address: Prof Elaine Kay (IACR President)

09.00-10.30 **Proferred Paper Session 1** (5 x 15 minutes)

Chairs: Dr. Ann Hopkins (RCSI) and Dr. Lorraine O'Driscoll (TCD)

09.00-09.15 **DEVELOPMENT AND FUNCTIONAL VALIDATION OF A NOVEL ANTI-ANGIOGENIC COMPOUND FOR USE IN COLORECTAL**

CANCER

AG Murphy^{1,2}, R Casey³, M Tosetto¹, J Hyland¹, E Conroy², W

Gallagher², D Fennelly¹, B Kennedy², J O'Sullivan³

¹Education & Research Centre, St Vincent's University Hospital, Dublin, ²UCD School of Biomolecular and Biomedical Sciences, University College Dublin, Dublin, ³Institute of Molecular Medicine,

Trinity College Dublin, Dublin

09.15-09.30 MIR-187 IS AN INDEPENDENT PROGNOSTIC FACTOR IN BREAST CANCER AND CONFERS INCREASED INVASIVE

POTENTIAL IN VITRO

L Mulrane¹, SF Madden², DJ Brennan^{1, 3}, G Gremel¹, SF McGee¹, S McNally¹, F Martin¹, JP Crown⁴, K Jirstrom⁵, DG Higgins⁶, WM Gallagher¹, DP O'Connor^{1, 1}Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin, ²Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, ³Queensland Centre for Gynaecological Cancer, University of Queensland, Brisbane, Australia, ⁴St. Vincent's

University of Queensland, Brisbane, Australia, St. Vinc

⁵Department of Clinical Sciences, Division of Pathology, Lund University, Lund, Sweden, ⁶UCD School of Medicine and Medical

Science, University College Dublin, Dublin

09.30-09.45 WHOLE GENOME SEQUENCING OF MULTIPLE METASTATIC TUMOURS FROM A PATIENT WITH CUTANEOUS MELANOMA TO

INVESTIGATE TUMOUR HETEROGENEITY

SJ Furney^{1,2}, S Turajlic², Y Odoku², A Hayes³, G Stamp³, J Larkin³, M Gore³, R Marais^{1, 1}Molecular Oncology Group, Paterson Institute for Cancer Research, Manchester, ²Cancer Biology, Institute of Cancer Research, London, ³, Royal Marsden Hospital, London,



09.45-10.00	TARGETING COLON CANCER CELL NF-KB REGULATES TUMOR-ASSOCIATED MACROPHAGE POLARIZATION AND ENHANCES ANTI-TUMOR IMMUNE RESPONSE AE Ryan ^{1,2} , A Colleran ¹ , A O'Gorman ¹ , L O'Flynn ² , J Pindjacova ² , P Lohan ² , M Nosov ² , C Mureau ¹ , LJ Egan ¹ ¹Pharmacology & Therapeutics, NUI Galway, Galway, ¹Immunology Group, REMEDI, NUI Galway, Galway,	
10.00-10.15	LOSS OF SATB1 PROMOTES COLON CANCER PROGRESSION THROUGH THE ACQUISITION OF A CHROMOSOMALLY INSTABLE PHENOTYPE K Naicker ¹ , Y Fan ¹ , D Brennan ¹ , R Casey ² , W Gallagher ¹ , J O'Sullivan ² , D O'Connor ^{1, 1} UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, ² Department for Surgery, Institute of Molecular Medicine, Trinity College Dublin, Dublin	
10.15-10.45	Tea/Coffee/Posters & Meet the Sponsors	
10.45-12.45	Plenary Session 1: Targeting Haematological malignancies	
Chairs: Prof. Mark Lawler (Queen's University Belfast) & Dr. Sharon McKenna (UCC)		
10.45-11.15	Dr. Jude Fitzgibbon (Barts Cancer Centre, UK)) 'Personalised Epigenetic Therapy in Germinal Centre Lymphomas'	
11.15-11.45	Dr Maria Figueroa (University of Michigan, Detroit) "Understanding the Epigenetic Basis of Leukemias: New options for therapeutic targeting"	
11.45-12.15	Dr. Peter O'Gorman (Mater Hospital, Dublin) "Bench to bedside translation of targeted therapeutics in Multiple Myeloma".	



	Thursday 28° February 2013	
12.15-12.45	Special Guest Lecture:	
	Dr. Jos Jonkers (Netherlands Cancer Institute) 'Studying therapy response and resistance in mouse models of human breast cancer'	
12.45-13.45	Lunch, Trade Exhibition and Posters	
13.45-15.15	Plenary Session 2: Mouse Models Of Cancer	
Chairs: Dr. Darran O'Connor (UCD) and Dr Corrado Santocanale (NUIG)		
13.45-14.15	Dr. Owen Sansom (Beatson, UK) 'Using mouse models to stratify treatments: Kras mutation and resistance to therapy'	
14.15-14.45	Dr Philip O'Halloran (Neurosurgery Registrar, Beaumont Hospital & Dept of Physiology & Medical Physics, Royal College of Surgeons in Ireland): "Interrogation of Novel Treatment Strategies in Glioblastoma implementing clinically relevant rodent models: A Multi-Modality Molecular Imaging Approach"	
14.45-15.15	Dr. Matt Smalley (Cardiff University) 'Using mouse models to dissect breast cancer heterogeneity'	
15.15- 15.45	Tea/Coffee/Posters & Meet the Sponsors	
15.45-16.30	Oral Poster Presentations (6 x 7 min presentations)	
Chairs: Prof. John Fitzpatrick (ICS) & Dr Sinead Walsh (ICS)		
15.45-15.52	THE c-MET-JAK1/2-STAT3 SIGNALLING AXIS IS A CRITICAL MEDIATOR OF RESISTANCE TO MEK INHIBITION IN KRAS MUTANT COLORECTAL CANCER S Van Schaeybroeck ¹ , M Kalimutho ¹ , P Dunne ¹ , C Fenning ¹ , R Carson ¹ , W Allen ¹ , DB Longley ¹ , PG Johnston ¹ Oncology, Centre for Cancer Research and Cell Biology, Belfast	
15.52-15.59	miR-29 MODULATES Cdc7 KINASE DURING REPLICATION STRESS LR Barkley ¹ , C Santocanale ^{1, 1} National Centre for Biomedical Engineering Science, National University of Ireland, Galway	



15.59-16.06

CELLULAR FATES HAVE THE POTENTIAL TO PREDICT CHEMORESPONSE IN TRIPLE NEGATIVE BREAST CANCER (TNBC)

Elma A. O'Reilly^{1,2}, Shiva Sharma^{1,2}, Rut Klinger¹, Michele Harrison³, Karolina Weiner-Gorzel¹, Ciara Kelly⁴, Aoife Maguire⁵, Janet McCormack⁶, Susie Conlon³, Susan Aherne⁵, Caitlin Beggan³, Richard Bambury⁴, Tomas Lyons⁴, Tiffany H. Dorsey⁷, Stefan Ambs⁷, Darran O'Connor¹, Cecily Quinn⁵, John McCaffrey⁴, Reem Salman², Sharon A. Glynn⁸, Fiona Furlong¹, Malcolm Kell², Amanda McCann¹, (1) UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science, Belfield, Dublin; (2) Department of Surgery, Mater Misericordiae Hospital, Dublin; (3) Department of Pathology, Mater Misericordiae Hospital, Dublin; (4) Department of Oncology, Mater Misericordiae Hospital, Dublin; (5) Department of Pathology, St. Vincents University Hospital, Dublin 4; (6) Department of Digital Pathology Core Facility, UCD Conway Institute of Biomolecular and Biomedical Research, Belfield; (7) National Cancer Institute, Bethesda, Maryland, USA; (8) Prostate Cancer Institute, NUI Galway.

16.06-16.13

OBESITY DRIVES GENOMIC INSTABILITY AND RADIORESISTANCE IN OESOPHAGEAL CANCER

AM Mongan¹, N Lynam-Lennon¹, R Casey¹, L Marignol², S Maher¹, G Pidgeon¹, JV Reynolds¹, J O'Sullivan¹

Department of Surgery, Institue of Molecular Medicine/Trinity College Dublin, Dublin 8, ²Department of Radiation Therapy, Institue of Molecular Medicine/Trinity College Dublin, Dublin 8

16.13-16.20

LOW INCIDENCE OF BRAFV600E MUTATION AMONG MELANOMA PATIENTS IN IRELAND

K van den Hurk¹, B Balint¹, S Toomey², L Unwin¹, K Sheahan³, E McDermott⁴, I Murphy⁴, J van den Oord⁵, M Rafferty¹, B Hennessy², WM Gallagher^{1, 6, 1}OncoMark Ltd., NovaUCD, Dublin, ²Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, ³Department of Pathology, St. Vincent's University Hospital, Dublin, ⁴Department of Surgery, St. Vincent's University Hospital, Dublin, ⁵Laboratory of Morphology and Molecular Pathology, Katholieke Universiteit Leuven, Leuven, Belgium, ⁶Cancer Biology and Therapeutics Laboratory, UCD Conway Institute, Dublin



16.20-16.27	CANDIDATE DRUG SCREENING IN AN ANIMAL MODEL OF CN-AML LMJ Kettyle ¹ , JM Ramsey ¹ , SD Zhang ¹ , KI Mills ¹ , A Thompson ¹ Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast
16.30-17.15	Sponsor Talks (focused on technology and platforms)
17.30-18.30	Irish Cancer Society Lecture Introduced by: John McCormack, (ICS)
	Dr. René Bernards (Netherlands Cancer Institute (NKI), Amsterdam) "Using functional genetics to optimize the treatment of cancer".
19.00-22.00	Formal Poster Session, Trade exhibition/ wine reception/buffet dinner Crowne Plaza Hotel, Santry



09.00-10.30 **Proferred Paper 2 Session** (5 x 15 minutes)

Chairs: Dr Leonie Young (RCSI) & Dr. Paul Mullan (Queens, Belfast)

09.00-09.15

DEVELOPMENT OF COMPREHENSIVE MOLECULAR PORTRAITS OF LOBULAR BREAST CANCER WITHIN THE RATHER (RATIONAL THERAPY FOR BREAST CANCER) CONSORTIUM

Yue Fan^{1,7}, Finbarr Tarrant^{1,7}, Darran P. O'Connor^{1,7}, Ian Majewski^{4,7}, Justine Peeters^{3,7}, Leanne de Koning^{5,7}, Kate Connor^{1,7}, Jeroen Heijmans^{3,7}, Mireille Snel^{3,7}, Tesa Severson^{4,7}, Astrid Bootsma^{4,7}, Magali Michaut⁴, Lorenza Mittempergher⁴, Thierry Dubois^{5,7}, Iris Simon^{3,7}, Carlos Caldas^{6,7}, Rene Bernards^{3,4,7}, William M. Gallagher^{1,2,7, 1}University College Dublin, Dublin Ireland, ² OncoMark Limited, Dublin, Ireland, ³ Agendia NV, Amsterdam, The Netherlands, ⁴The Netherlands Cancer Institute NKI-AVL, Amsterdam, The Netherlands, ⁵Institut Curie, Paris, France, ⁶Cambridge Research Institute, Cambridge, UK., ⁷RATHER Consortium.

09.15-09.30

SUPPRESSION OF THE PROSTAGLANDIN EP1 RECEPTOR REDUCES COLON CANCER CELL INVASION AND METASTASIS GP O'Callaghan^{1,2}, M Reagan², L Flores², Y Zhang², A Roccaro², F Shanahan¹, I Ghobrial², AM Houston¹

¹Department of Medicine, UCC, Cork, ²Department of Medical Oncology, Harvard Medical School, Boston, MA, USA

09.30-09.45

EXOSOMAL-MIRNAS: POTENTIAL COMMUNICATORS IN TRIPLE-NEGATIVE BREAST CANCER

K O'Brien¹, S Rani¹, C Corcoran¹, S McDonnell², L Hughes², J Crown³, M Radomski ¹, L O'Driscoll¹,

¹School of Pharmacy and Pharmaceutical Sciences & TBSI, Trinity College Dublin, Dublin,

²School of Chemical and Bioprocess Engineering, University College Dublin, Dublin, ³Molecular Therapeutics for Cancer Ireland, St. Vincent's University Hospital, Dublin



Main IACR Meeting Friday 1st March 2013

09.45-10.00	CHANGES IN MITOCHONDRIAL DYSFUNCTION AND ENERGY METABOLISM IN THE BARRETT'S OEOSPHAGUS TO ADENOCARCINOMA DISEASE SEQUENCE. J.J. Phelan ¹ , F. McCarthy ² , R. Feighery ¹ , N. O'Farrell ¹ , N. Lynam-Lennon ¹ , B. Doyle ³ , D. O'Toole ¹ , N. Ravi ¹ , J.V. Reynolds ¹ , J.N. O'Sullivan ^{1, 1} Department of Surgery, Trinity College Dublin, Institute of Molecular Medicine, St. James's Hospital, Dublin 8, ² Department of Clinical Medicine,, Institute of Molecular Medicine, St. James's Hospital, Dublin 8, ³ Department of Pathology, St. James's Hospital, Dublin 8 PALMITOYLATION OF CD44 REGULATES BREAST CANCER CELL MIGRATION VIA ALTERATIONS IN ITS LIPID RAFT AFFILIATION. IS Babina ¹ , AM Hopkins ^{1, 1} Surgery, Royal College of Surgeons in Ireland, Dublin 9	
10.30-11.00	Tea/Coffee/Posters & Meet the Sponsors	
11.00-12.30	Plenary Session 3: Mitochondrial Dysfunction & Altered Metabolism in Cancer	
Chairs: Dr. Jacintha O'Sullivan (TCD) and Dr Amanda McCann (UCD)		
11.00-11.30	Dr. Jason Bielas (Fred Hutchinson Cancer Centre, Seattle 'Mechanism and Clinical Utility of Nuclear and Mitochondrial DNA Mutations in Cancer'	
11.30 -12.00	Prof. Michael Lisanti (University of Manchester, UK) 'Changing the Cancer Paradigm: Novel Strategies for Personalized Medicine and New Anti-Cancer Therapies'	
12.00-12.30	Dr. Patrick Pollard (University of Oxford, UK) The Metabolism of Hereditary Renal Cancer	
12.30-13.30 LUNC	CH, Trade Exhibitions and Posters	
13.30-14.00	AGM (All welcome)	



Main IACR Meeting Friday 1st March 2013

14.00-15.30 Plenary Session 4: Kinases and Phosphatases in Cancer:

potential therapeutic strategies

Chairs: Dr. Pat Kiely and Dr. Dan Longley

14.00-14.30 Professor Nigel Pyne (University of Strathclyde, Glasgow)

'The role of sphingosine kinase in cancer'

14.30-15.00 Professor Nicholas K. Tonks, PhD, FRS

Drugging the undruggable: new approaches to inhibition of

PTP1B in cancer

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

15.00-15.30 Professor Walter Kolch (University College Dublin, Dublin)

"Regulation of the pro-apoptotic MST2/Hippo pathway by Raf

kinases"

15.30-16.00 Tea/Coffee/Posters & Meet the Sponsors

16.00-17.00 EACR Young Scientist Talks followed by presentation of awards

Chairs: Dr. Jacintha O'Sullivan (TCD) & Professor Elaine Kay (RCSI)

16.00-16.25 ADAM8: A NOVEL THERAPEUTIC TARGET AND

BIOMARKER FOR BREAST CANCER?

AM Dagg^{1,2}, M Mullooly^{1,2}, F Caiazza^{1,2}, JW Bartsch³, MJ Duffy^{2,4}, **PM**

McGowan^{1,2}

¹Education and Research Centre, St. Vincent's University Hospital, Dublin 4, ²School of Medicine and Medical Science, University College

Dublin, Dublin 4, ³Dept. of Neurosurgery, University of Marburg, Marburg, Germany, ⁴UCD Clinical Research Centre, St. Vincent's

University Hospital, Dublin 4

16.25-16.50 MECHANISTIC INTERACTIONS OF MICRORNA AND DNA

METHYLATION AND ITS IMPLICATION ON THE CANCER

EPIGENOME

S Das^{1,2}, K Bryan^{1,2}, N Foley^{1,2}, P Buckley^{1,2}, R Stallings^{1,2}

¹Molecular and cellular therapeutics, Royal college of surgeons in Ireland, Dublin, ²Children's research centre, Our Lady's Children's

hospital, Dublin

16.55 Close of Meeting

19.30 -22.00 GALA DINNER, Crowne Plaza Hotel, Santry

Awarding of Prizes at Gala Dinner

(Supported by an educational grant from Millennium Pharmaceuticals, Inc., The Takeda Oncology Company)